Maprotiline: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{PB}}
|authorTag={{PB}}
|genericName=Maprotiline
|aOrAn=a
|aOrAn=a
|drugClass=tetracyclic antidepressant
|indication=bipolar disorder, depressed phase, depression, dysthymia, mixed anxiety and depressive disorder
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=<b>Condition 1</b>
|fdaLIADAdult=* Bipolar disorder, depressed phase
 
:*Outpatients: 75 mg/day PO (2-3 divided doses) for 2 weeks; may increase in 25 mg increments up to a max of 225 mg/day in single or divided doses
* Dosing Information
:*Inpatients: 100-150 mg/day PO (2-3 divided doses) for 2 weeks; may increase in 25 mg increments up to a max of 225 mg/day in single or divided doses
 
:*Maintenance: 75-150 mg/day PO in single or divided doses
:: (Dosage)
*Depression
|offLabelAdultGuideSupport=<b>Condition 1</b>
:*
 
*Dysthymia
* Developed by: (Organization)
:*
 
*Mixed anxiety and depressive disorder
* Class of Recommendation: (Class) (Link)
:*
 
|offLabelAdultNoGuideSupport=*Pain
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelAdultNoGuideSupport=<b>Condition 1</b>
 
* Dosing Information


:* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Maprotiline in adult patients.
:* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Maprotiline in adult patients.
|fdaLIADPed=<b>Condition 1</b>
|offLabelPedNoGuideSupport=:* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Maprotiline in pediatric patients.
 
* Dosing Information
 
:: (Dosage)
|offLabelPedGuideSupport=<b>Condition 1</b>
 
* Developed by: (Organization)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelPedNoGuideSupport=<b>Condition 1</b>
 
* Dosing Information
 
:* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Maprotiline in pediatric patients.
|contraindications=* Condition 1
|contraindications=* Condition 1
* Condition 2
* Condition 2
Line 108: Line 83:
* (Drug 3)
* (Drug 3)
:* (Description)
:* (Description)
|drugBox={{drugbox2
| Watchedfields = changed
| verifiedrevid = 477169275
| IUPAC_name = ''N''-Methyl-9,10-ethanoanthracene-9(10''H'')-propanamine
| image = 200px-Maprotiline.svg.png
| width = 200
| image2 = 250px-Maprotiline3Dan.gif
| width2 = 250
<!--Clinical data-->
| Drugs.com = {{drugs.com|monograph|maprotiline-hydrochloride}}
| MedlinePlus = a682158
| pregnancy_US = B3
| legal_AU = S4
| legal_US = Rx-only
| routes_of_administration = oral, intramuscular, intravenous (infusion)
<!--Pharmacokinetic data-->
| bioavailability = 66 to 70%
| protein_bound = 88%
| metabolism = hepatic
| elimination_half-life = 27-58 hours
| excretion = biliar (30%) and urine (57%) as gluconurides, 3 to 4% as unchanged drug
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 10262-69-8
| ATC_prefix = N06
| ATC_suffix = AA21
| ATC_supplemental =
| PubChem = 4011
| IUPHAR_ligand = 2402
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00934
| ChemSpiderID = 23719117
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2U1W68TROF
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02566
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 21731
<!--Chemical data-->
| C=20 | H=23 | N=1
| molecular_weight = 277.403 g/mol
|  smiles = CNCCC[C@@]12C3=CC=CC=C3[C@@H](C4=CC=CC=C14)CC2
|  InChI = 1/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3/t15-,20+
|  InChIKey = QSLMDECMDJKHMQ-GSXCWMCIBU
|  StdInChI = 1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3/t15-,20+
|  StdInChIKey = QSLMDECMDJKHMQ-GSXCWMCISA-N
}}
|mechAction=It exerts blocking effects at the following postsynaptic receptors:
|mechAction=It exerts blocking effects at the following postsynaptic receptors:
* Strong : alpha<sub>1</sub>
* Strong : alpha<sub>1</sub>

Revision as of 19:10, 26 May 2014

Maprotiline
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Maprotiline is a tetracyclic antidepressant that is FDA approved for the {{{indicationType}}} of bipolar disorder, depressed phase, depression, dysthymia, mixed anxiety and depressive disorder. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Bipolar disorder, depressed phase
  • Outpatients: 75 mg/day PO (2-3 divided doses) for 2 weeks; may increase in 25 mg increments up to a max of 225 mg/day in single or divided doses
  • Inpatients: 100-150 mg/day PO (2-3 divided doses) for 2 weeks; may increase in 25 mg increments up to a max of 225 mg/day in single or divided doses
  • Maintenance: 75-150 mg/day PO in single or divided doses
  • Depression
  • Dysthymia
  • Mixed anxiety and depressive disorder

Off-Label Use and Dosage (Adult)

Non–Guideline-Supported Use

  • Pain
  • There is limited information about Off-Label Non–Guideline-Supported Use of Maprotiline in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Maprotiline FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Non–Guideline-Supported Use

  • There is limited information about Off-Label Non–Guideline-Supported Use of Maprotiline in pediatric patients.

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Conidition 1

(Description)

Adverse Reactions

Clinical Trials Experience

Central Nervous System

(list/description of adverse reactions)

Cardiovascular

(list/description of adverse reactions)

Respiratory

(list/description of adverse reactions)

Gastrointestinal

(list/description of adverse reactions)

Hypersensitive Reactions

(list/description of adverse reactions)

Miscellaneous

(list/description of adverse reactions)

Postmarketing Experience

Central Nervous System

(list/description of adverse reactions)

Cardiovascular

(list/description of adverse reactions)

Respiratory

(list/description of adverse reactions)

Gastrointestinal

(list/description of adverse reactions)

Hypersensitive Reactions

(list/description of adverse reactions)

Miscellaneous

(list/description of adverse reactions)

Drug Interactions

  • (Drug 1)
  • (Description)
  • (Drug 2)
  • (Description)
  • (Drug 3)
  • (Description)

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Maprotiline in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Maprotiline in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Maprotiline during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Maprotiline in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Maprotiline in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Maprotiline in geriatric settings.

Gender

There is no FDA guidance on the use of Maprotiline with respect to specific gender populations.

Race

There is no FDA guidance on the use of Maprotiline with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Maprotiline in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Maprotiline in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Maprotiline in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Maprotiline in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Maprotiline Administration in the drug label.

Monitoring

There is limited information regarding Maprotiline Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Maprotiline and IV administrations.

Overdosage

There is limited information regarding Maprotiline overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Px
Template:Px
Maprotiline
Systematic (IUPAC) name
N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine
Identifiers
CAS number 10262-69-8
ATC code N06AA21
PubChem 4011
DrugBank DB00934
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 277.403 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 66 to 70%
Protein binding 88%
Metabolism hepatic
Half life 27-58 hours
Excretion biliar (30%) and urine (57%) as gluconurides, 3 to 4% as unchanged drug
Therapeutic considerations
Pregnancy cat.

?(US)

Legal status

Prescription Only (S4)(AU) [[Prescription drug|Template:Unicode-only]](US)

Routes oral, intramuscular, intravenous (infusion)

Mechanism of Action

It exerts blocking effects at the following postsynaptic receptors:

  • Strong : alpha1
  • Moderate : 5-HT2, muscarinic, H1, D2
  • Weak : alpha2
  • Extremely weak : 5-HT1

The pharmacologic profile of Maprotiline explains its antidepressant, sedative, anxiolytic, sympatholytic, and anticholinergic activities. Additionally, it shows a strong antagonism against Reserpine-induced effects in animal studies, as do the other 'classical' antidepressants. Although Maprotiline behaves in most regards as a 'first generation antidepressant' it is commonly referred to as 'second generation antidepressant'.

Sedation has a fast onset (the same day), while remission of the depression itself is noted usually after a latent period of one to four weeks.

Maprotiline does not brighten up the mood in nondepressed persons.

Structure

There is limited information regarding Maprotiline Structure in the drug label.

Pharmacodynamics

There is limited information regarding Maprotiline Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Maprotiline Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Maprotiline Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Maprotiline Clinical Studies in the drug label.

How Supplied

There is limited information regarding Maprotiline How Supplied in the drug label.

Storage

There is limited information regarding Maprotiline Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Maprotiline |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Maprotiline |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

For patient information, please click here.

Precautions with Alcohol

Alcohol-Maprotiline interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Maprotiline Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Maprotiline Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Maprotiline&oldid=973557"